Last reviewed · How we verify

Arvinas Androgen Receptor, Inc. — Portfolio Competitive Intelligence Brief

Arvinas Androgen Receptor, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aragon Pharmaceuticals, Inc. · 1 shared drug class
  2. Astellas Pharma · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. City of Hope Medical Center · 1 shared drug class
  5. Pfizer Inc. · 1 shared drug class
  6. Tata Memorial Centre · 1 shared drug class
  7. Triple Hair Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arvinas Androgen Receptor, Inc.:

Cite this brief

Drug Landscape (2026). Arvinas Androgen Receptor, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arvinas-androgen-receptor-inc. Accessed 2026-05-17.

Related